Bristol Myers (BMY) announced that the European Commission (EC) has approved the subcutaneous formulation of Opdivo (nivolumab) across multiple solid tumor indications. The decision applies to all 27 EU member states, as well as Iceland, Norway and Liechtenstein.Nivolumab for subcutaneous (SC) use, co-formulated with recombinant human hyaluronidase (rHuPH20), is indicated across multiple previously approved adult solid tumors as monotherapy, monotherapy maintenance following completion of nivolumab plus Yer ...